Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Obstetrics and Gynecology - Gynecologic Oncology, 2017
Obstetrics and Gynecology, 2016
Ann B. Barshinger Cancer Institute
2102 Harrisburg Pike
Lancaster, PA 17601
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine Lancaster General Health.
Stashwick, Czernieck BJ, Tanyi JL: Dendritic Cell Vaccine Therapy for Ovarian Cancer Chapter. Ovarian Cancer Immunotherapy: Current Perspectives Chpt 8 : 2018.
O'Hara MH, Stashwick C, Plesa G, Tanyi JL: Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers. Immunotherapy 9(9):767-780 : 2017.
Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH: Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. J Immunotherapy 40(3):104-107 : 2017.
Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler N, Powell DJ Jr: Tumor regression and delayed onset toxicity following B7-H4 CAR T cell Therapy. Mol Ther 24(11):1987-1999 : 2016.
Dean LT, Zhang X, Latif N, Giuntoli R, Lin L, Haggerty A, Kim S, Shalowitz D, Stashwick C, Simpkins F, Burger R, Morgan M, Schmitz K: Race-based disparities in loss of functional independence after hysterectomy for uterine cancer. Support Care Cancer 24(8):3573-80 : 2016.
O’Hara M, Stashwick C, Haas AR, Tanyi JL: Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8(4):449-60 : 2016.
Urbanksa K, Stashwick C, Powell DJ: Follicle-stimulating hormone receptor as a target in the redirected T-cell therapy for cancer. Cancer Immunology Research 3(10):1130-7 : 2015.
Urbanska K, Lynn R, Stashwick C, Thakur A, Lum L, Powell DJ: Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J Transl Med 13;12:347 : 2014.
Smith J*, Stashwick C*, Powell DJ (*co-first authors): B7-H4 as a potential target for immunotherapy for gynecologic cancer: A closer look. Gynecol Oncol 134(1):181-189 : 2014.
Stashwick C, Post MD, Arruda JS, Spillman, MA, Behbakht K, Davidson SA, Kelly MG: Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Int J Gynecol Cancer 21(8):1422-7 : 2011.
Ann B Barshinger Cancer Institute Lancaster General Health/Penn Medicine 2102 Harrisburg Pike
Phone: (617) 835-1405
Patient appointments: 800-789-7366
Find our contact forms and phone numbers or give feedback on a recent experience using Care to Share.
View test results, schedule appointments, or request prescription refills from the convenience of your computer or mobile device.
Learn about health system news and meet new providers in Progress Notes, Lancaster General Health's provider newsletter.